8-K
filed February 6, 2023, 6:59 PM ET
ticker CATX
CIK 0000728387
M&A
confidence high
sentiment neutral
materiality 0.85
Perspective Therapeutics, Inc. (CATX): M&A transaction — Isoray closes all-stock merger with Viewpoint; Spoor named CEO, Woods Chair
Perspective Therapeutics, Inc.
- Completed all-stock merger with Viewpoint; issued 136.5M shares (49% of pro forma) at 3.1642 exchange ratio.
- New CEO Thijs Spoor (ex-Viewpoint CEO) appointed; Lori Woods becomes Chairperson of the Board.
- Woods receives $504K severance, accelerated vesting of 1,007,498 stock options under separation agreement.
- Board expanded to five: Woods (Chair), Spoor, Morich, Williamson, and McCormick.
- Fiscal year changed from June 30 to December 31; transition Form 10-KT to be filed.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frank Morich was appointed as Director at Perspective Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
(iv) Dr. Frank Morich as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alan Hoffmann resigned as Director at Perspective Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lori A. Woods resigned as Chief Executive Officer at Perspective Therapeutics, Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
On February 1, 2023, and effective upon the Closing, Lori A. Woods gave notice of her resignation as the Chief Executive Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Philip Vitale resigned as Director at Perspective Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Johan (Thijs) Spoor was appointed as Chief Executive Officer at Perspective Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
the Board appointed: (i) Johan (Thijs) Spoor as Chief Executive Officer and a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Froman Williamson, III was appointed as Director at Perspective Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
(iii) Robert Froman Williamson, III as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lori A. Woods was appointed as Chairperson of the Board at Perspective Therapeutics, Inc..
- Action
- appointed
- Role
- Chairperson of the Board
Exact text from the filing
(ii) Lori A. Woods as Chairperson of the Board
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.99
Perspective Therapeutics, Inc.: The Board approved a change in the Company's fiscal year end from June 30 to December 31, effective immediately (effective 2023-01-31).
- Change
- fiscal year change
- Effective
- 2023-01-31
Exact text from the filing
On January 31, 2023, the Board approved a change in the fiscal year end of the Company from June 30 to December 31.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Perspective Therapeutics, Inc. completed an acquisition involving Viewpoint Molecular Targeting, Inc. (closed 2023-02-03).
- Action
- acquisition
- Counterparty
- Viewpoint Molecular Targeting, Inc.
- Closing
- 2023-02-03
Exact text from the filing
On February 3, 2023 (the " Closing Date "), the Company completed the merger (the " Closing ") of Isoray Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company (" Merger Sub "), with Viewpoint Molecular Targeting, Inc. (" Viewpoint ") (such transaction being the " Merger ").
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.